Tamoxifen May Boost PI3K Signaling to Increase Uterine Cancer Risk in Patients With Breast Cancer
Concurrent treatment with PI3K pathway inhibitors may benefit at-risk patients SAN ANTONIO – Uterine cancers that developed in patients...
Concurrent treatment with PI3K pathway inhibitors may benefit at-risk patients SAN ANTONIO – Uterine cancers that developed in patients...
Tumor biology, not race, was a more significant factor in predicting response to clinical trial treatment SAN ANTONIO – Analysis...
SAN ANTONIO – Black women experienced higher rates of breast cancer-related lymphedema than white women, and Black race was...
Elacestrant is the first oral selective estrogen receptor degrader to show clinical benefit over standard of care in a...
Imaging mass cytometry was feasible in a large clinical trial of atezolizumab in combination with chemotherapy SAN ANTONIO –...
The ESMO Scale for Clinical Actionability of molecular Targets (ESCAT) was highly predictive of the benefits of targeted therapies...
Next-generation sequencing for minimal residual disease was highly sensitive and more accurate than flow cytometry and monitoring of B-cell...
PHILADELPHIA – Today, the American Association for Cancer Research (AACR) and Pelotonia announced the establishment of a new grants...
PHILADELPHIA – A diet involving short-term, severe calorie restriction was safe, feasible, and resulted in a decrease of blood...
AACR expresses appreciation to Janet Woodcock, MD, for her excellent stewardship as FDA’s Acting Commissioner for the past 10...